ABcann Medicinals Inc (ABCN)

[Pr0drIv3]

Terms of the 15 millions debenture financing:

be convertible at the option of the holder into common shares of the Resulting Issuer (each, a “Share”) at any time prior to the close of business on the maturity date at a conversion price (the “Conversion Price”) equal to an amount which represents a 30% premium to the Issue Price per Subscription Receipt. Given that the Issue Price per Subscription Receipt is expected to be $0.80, it is expected that the Conversion Price will be $1.04 per Share. In the event that the Resulting Issuer completes a subsequent equity financing at a price below the Conversion Price, the Conversion Price will be adjusted downward to the price per share of any subsequent equity financing, subject to a floor price equal to the Issue Price per Subscription Receipt; and

So roughly, 15% dilution in 36 months? Any thought on that?


https://www.newcannabisventures.com/canadian-cannabis-producer-abcann-moves-closer-to-trading-publicly/